Alternative lower cost approach to the treatment of multiple myeloma. (A) Newly diagnosed and (B) relapsed. *Bortezomib may be preferred for intermediate- and high-risk patients. **Consider salvage ASCT in patients eligible for ASCT. †Any of the regimens listed for first relapse that the patient has not previously been exposed to.